K Rašlová, M Bogoev, I Raz, G Leth, MA Gall … - Diabetes research and clinical practice, 2004 - Elsevier This trial compared the efficacy and safety of basal-bolus therapy using either
the soluble basal insulin analogue insulin detemir (IDet) in combination with
meal-time rapid-acting analogue insulin aspart (IAsp), or NPH insulin (NPH) ... Cited by 160 - Related articles - All 8 versions
- ►diabetesjournals.org J Plank, M Bodenlenz, F Sinner, C Magnes, E … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Duration of action for insulin detemir was dose dependent and varied
from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6
units/kg, respectively. Interpolation of the dose-response relationships ... Cited by 129 - Related articles - All 9 versions
D Russell-Jones, R Simpson, B Hylleberg, E … - Clinical therapeutics, 2004 - Elsevier Methods: This was a 6-month, prospective, randomized, open-label, controlled,
parallel-group trial conducted at 92 sites in Europe and Australia. The trial
population included men and women with type 1 DM for at least 1 year aged ... Cited by 122 - Related articles - All 4 versions
TR Pieber, E Draeger, A Kristensen, V Grill - Diabetic Medicine, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 89 - Related articles - All 4 versions
A Fritsche, H Haring - International Journal of Obesity, 2004 - pr-ide.be Insulin detém ¡г and weight stability A Frfeche and H Häring S42 -2.5 -ah-
Insulin O- Conventional Chlorpropamide -я- Glibenclamide Metformin 3 6 9 Years
from randomisation Figure 1 Patients on all therapies gained weight during ... Cited by 64 - Related articles - BL Direct - All 5 versions
K Kolendorf, GP Ross, I Pavlic-Renar, G … - Diabetic Medicine, 2006 - interscience.wiley.com This study was published as an abstract at ADA 2004: Kølendorf K, Pavlic-Renar
I, Santeusanio F, Philothou A, Gall MA, Heller S. Insulin detemir is associated
with lower risk of hypoglycemia compared to NPH insulin in people with Type ... Cited by 56 - Related articles - BL Direct - All 6 versions
LF Meneghini, KH Rosenberg, C Koenen, MJ … - Diabetes Obes Metab, 2007 - journals.pcommed.com 1Diabetes Research Institute, University of Miami Miller School of Medicine,
Miami, FL, USA 2Epidemiology, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark
3Medical & Science, Novo Nordisk A/S, DK-2880, Bagsværd, Denmark 4Center ... Cited by 53 - Related articles - View as HTML - All 4 versions
T Heise, TR Pieber - Diabetes Obes Metab, 2007 - journals.pcommed.com While the advantages of the two basal insulin analogues, glargine and detemir,
over neutral protamine Hagedorn are well established, the relative merit of the
two compared with each other has been a matter of some controversy. The two ... Cited by 46 - Related articles - View as HTML - All 4 versions
TR Pieber, HC Treichel, B Hompesch, A … - Diabetic Medicine, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 44 - Related articles - BL Direct - All 5 versions
SCL Gough - Diabetes research and clinical practice, 2007 - Elsevier A recent meta-analysis evaluated trials of the rapid-acting analogues insulin
lispro and insulin aspart, performed before the introduction of the basal
analogues, insulin glargine and insulin detemir. This article reviews the ... Cited by 43 - Related articles - All 21 versions
